Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CF Cauldron FermCompany profile Provides continuous hyper-fermentation technology for industrial-scale bio-production Provides continuous hyper-fermentation technology for industrial-scale bio-production | $13.3M | Series A2Series A | Biotech | Australia | Investors | |
| VM Virchow MedicalCompany profile Provides biopsy specimen stewardship and expands access to precision oncology Provides biopsy specimen stewardship and expands access to precision oncology | $4M | Seed | Biotech, Healthtech | United States | Investors | |
| GP Gilgamesh PharmaCompany profile Develops novel chemical entities for psychiatric and neurological disorders Develops novel chemical entities for psychiatric and neurological disorders | $60M | Series A | Biotech | United States | Investors | |
| R RyboDynCompany profile Decodes the dark proteome using an AI-powered novel sequencing and discovery platform to reveal novel cancer targets Decodes the dark proteome using an AI-powered novel sequencing and discovery platform to reveal novel cancer targets | $10M | Seed | Biotech | United States | Investors | |
| N NanoZymeXCompany profile NanoZymeX develops a lipid-nanoparticle platform for enzyme replacement therapy. NanoZymeX develops a lipid-nanoparticle platform for enzyme replacement therapy. | €160K | Pre-SeedPre-seed | Biotech | Switzerland | Investors | |
| ET Develops novel therapies for beta globin disorders | $32M | GrantUndisclosed | Biotech | United States | Investors | |
| AT Amani TherapeuticsCompany profile Biotechnology company developing combination medicines for serious neuropsychiatric disorders. Biotechnology company developing combination medicines for serious neuropsychiatric disorders. | $25M | Series A | Biotech | United States | Investors | |
| OC Oryon Cell TherapiesCompany profile Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders | $21M | Series A | Biotech | United States | Investors | |
| CT Congruence TherapeuticsCompany profile Develops small molecule correctors for diseases of protein misfolding Develops small molecule correctors for diseases of protein misfolding | $39.5M | Series B | Biotech | Canada | Investors | |
| HU Health UniverseCompany profile Provides AI infrastructure for healthcare organizations to integrate and govern autonomous agents Provides AI infrastructure for healthcare organizations to integrate and govern autonomous agents | $6M | Seed | Biotech, Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.